Nrx pharmaceuticals reports third quarter 2022 financial results and provides business update

Completed a technology transfer, submitted a new manufacturing file to the united states ("u.s.") food and drug administration ("fda"), and released new drug produced with processes designed to support commercial-stage manufacturing of a phase 3 investigational drug on track to report data from ongoing phase 2 clinical trial of nrx-101 in patients with bipolar depression with sub-acute suicidal ideation and behavior (ssib) in 1q 2023 company has received numerous partnering inquiries for nrx-101 plan to initiate registrational phase 3 clinical trial of nrx-101 in patients with bipolar depression with acute suicidal ideation and behavior (asib) by year-end; data readout expected in 3q 2023 commenced phase 2 clinical trial planning of nrx-101 for post-traumatic stress disorder ("ptsd") ended quarter with $18.2 million in cash and cash equivalents and announced completion of a subsequent unsecured debt financing on november 7, 2022, providing net proceeds of $10.0 million to support the nrx pharmaceuticals' pipeline of life-saving therapeutics radnor, pa. , nov. 14, 2022 /prnewswire/ -- nrx pharmaceuticals, inc. (nasdaq: nrxp) ("nrx pharmaceuticals", the "company"), a clinical-stage biopharmaceutical company, today announced its financial results for the third quarter of 2022 and provided a business and clinical update.
NRXP Ratings Summary
NRXP Quant Ranking